Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15505973 | 0.83 | DPP4 (0.32) | DPP4 | |
| SCHEMBL19017302 | 0.83 | DPP4 (0.32) | DPP4NOTUM | |
| SCHEMBL22878838 | 0.78 | DPP4 (0.30) | DPP4 | |
| SCHEMBL23210583 | 0.71 | DPP4 (0.36) | DPP4NOTUM | |
| SCHEMBL436995 | 0.70 | P2RX7 (0.36) | — | |
| SCHEMBL2736028 | 0.70 | PDPK1 (0.44) | DPP4NOTUM | |
| SCHEMBL9944479 | 0.68 | DPP4 (0.49) | DPP4NOTUM | |
| SCHEMBL22843789 | 0.68 | SLC2A2 (0.32) | DPP4NOTUM | |
| SCHEMBL21672409 | 0.68 | — | — | |
| SCHEMBL23085724 | 0.67 | PIK3CD (0.41) | DPP4NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043629-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043629-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20230322732-A1 | RIP1 Inhibitory Compounds and Methods for Making and Using the Same | RIGEL PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322732-A1 | RIP1 Inhibitory Compounds and Methods for Making and Using the Same | RIGEL PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230310454-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230310454-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230227469-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230227469-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-05-11 | — | — | US | disclosed |
| US-8435978-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-05-07 | — | — | US | disclosed |
| US-8263598-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-09-11 | — | — | US | disclosed |
| US-8178535-B2 | Substituted sulfonamide compounds having bradykinin 1 receptor activity and use thereof as medicaments | GRUENENTHAL GMBH (DE) | 2012-05-15 | — | — | US | disclosed |
| US-20100324009-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-12-23 | — | — | US | disclosed |
| US-20100317644-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20090298812-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090203672-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-08-13 | — | — | US | disclosed |
| US-20090186899-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310454-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | DPP4 2441/4885NOTUM 3388/4885 |
| US-20100317644-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | DPP4 402/4885NOTUM 2599/4885 |
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | ENTPD5, ENTPD1, SLC29A1 | DPP4 482/4885NOTUM 4466/4885 |
| US-12043629-B2 | RIP1K inhibitors | RIPK1, RIPK2, RIPK3 | DPP4 1861/4885NOTUM 3573/4885 |
| US-20100324009-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | DPP4 402/4885NOTUM 2599/4885 |
| US-20230322732-A1 | RIP1 Inhibitory Compounds and Methods for Making and Using the Same | RIPK1, RIPK2, RIPK3 | DPP4 2441/4885NOTUM 3388/4885 |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | SULT2A1, STS, SULT1A1 | DPP4 402/4885NOTUM 2599/4885 |
| US-20090186899-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, NPSR1 | DPP4 2792/4885NOTUM 4221/4885 |
| US-20090298812-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, TRPV1 | DPP4 1878/4885NOTUM 2878/4885 |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | DPP4 890/4885NOTUM 1463/4885 |
| US-20090203672-A1 | Substituted Sulfonamide Compounds | RPS4X, RPS4Y1, CACNA1A | DPP4 2636/4885NOTUM 4146/4885 |
| US-20230227469-A1 | RIP1K INHIBITORS | RIPK1, RIPK2, RIPK3 | DPP4 1861/4885NOTUM 3573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.